---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-26-018161"
form_type: "8-K"
ticker: "ALLR"
cik: "0001860657"
company_name: "Allarity Therapeutics, Inc."
filed_at: "2026-02-19T23:59:59+00:00"
generated_at: "2026-05-16T01:48:52.206539+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Allarity Therapeutics doses first patients in VA-funded Phase 2 trial of stenoparib + temozolomide for relapsed SCLC

## Summary
- First patients dosed with stenoparib and temozolomide in Phase 2 trial for relapsed small cell lung cancer (SCLC).
- Trial fully funded by U.S. Department of Veterans Affairs, enrolling at 11 VA medical centers nationwide.
- Stenoparib is a dual PARP and WNT pathway inhibitor; prior PARP inhibitors limited by hematologic toxicity.
- CEO cites fast enrollment and high unmet need; ~60-70% of SCLC patients present with extensive-stage disease.
- Stenoparib crosses blood-brain barrier, relevant for SCLC brain metastases.

## SEC filing metadata
- accession: 0001213900-26-018161
- form_type: 8-K
- ticker: ALLR
- cik: 0001860657
- company_name: Allarity Therapeutics, Inc.
- filed_at: 2026-02-19T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1860657/000121390026018161/0001213900-26-018161-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1860657/000121390026018161/ea0277546-8k_allarity.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-26-018161
- JSON: https://secwatch.observer/filing/0001213900-26-018161.json
- Plain text: https://secwatch.observer/filing/0001213900-26-018161.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.